d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. - Wikidata - awgldk - TriplyDB

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.

http://www.wikidata.org/entity/Q45711274

about

The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion Copper and iron in Alzheimer's disease: a systematic review and its dietary implications.Ceruloplasmin/Transferrin ratio changes in Alzheimer's disease Zinc and Copper in Alzheimer's Disease.Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease.The effect of formalin fixation on the levels of brain transition metals in archived samples.Clinically tested drugs for Alzheimer's disease.Copper modulation as a therapy for Alzheimer's disease?Paradigm shift in treatment of Alzheimer's disease: zinc therapy now a conscientious choice for care of individual patients.Schizandrin, an antioxidant lignan from Schisandra chinensis, ameliorates Aβ1-42-induced memory impairment in mice Serum copper in Alzheimer's disease and vascular dementia.Assessment of the effects of glutamic acid decarboxylase antibodies and trace elements on cognitive performance in older adults Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment.Therapeutics for Alzheimer's disease based on the metal hypothesis Trace element levels and cognitive function in rural elderly Chinese Copper in Alzheimer's disease: too much or too little?Novel drug targets based on metallobiology of Alzheimer's disease.Metal attenuating therapies in neurodegenerative disease.Modulating metals as a therapeutic strategy for Alzheimer's disease.Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects.Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures.Biological metals and metal-targeting compounds in major neurodegenerative diseases.Zinc in Alzheimer's Disease: A Meta-Analysis of Serum, Plasma, and Cerebrospinal Fluid Studies.In vitro studies of 3-hydroxy-4-pyridinones and their glycosylated derivatives as potential agents for Alzheimer's disease.Serum Copper, Zinc, and Iron Levels in Patients with Alzheimer's Disease: A Meta-Analysis of Case-Control Studies.Commentary: The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease.Serum Iron, Zinc, and Copper Levels in Patients with Alzheimer's Disease: A Replication Study and Meta-Analyses.The Relationship Between Copper, Iron, and Selenium Levels and Alzheimer Disease.Metals and Alzheimer's Disease: How Far Have We Come in the Clinic?Cu(atsm) Attenuates Neuroinflammation Role of amyloid-β–metal interactions in Alzheimer’s disease Cu selective chelators relieve copper-induced oxidative stress

P2860

Q33755982-1920E54E-919D-4F8F-A7F3-4AFC3049DDEE Q34186434-CE416620-634B-4153-9A71-78BF2F47A06A Q34201410-D72FB22B-1AFE-40B4-B222-871E49386D02 Q34460631-CE03FF9D-D1BD-4219-9DA2-173C1CABF799 Q34469983-A16D4B76-9FE9-44E0-B843-557CA714D39C Q34660301-E5B04392-276A-4D82-8C01-50DF8A88C5CF Q35085311-B9452A61-4376-44DA-9E18-1F2961F46CDB Q35164747-4C3521DC-6C25-439F-AF24-16A18AACF8EE Q35184353-1C4F76A1-8942-4644-B421-38B5D62CCCCA Q35226905-62EA3898-4784-4B75-9187-A65B13343336 Q36102657-E308C12C-3381-4470-90DE-6B292A89FED1 Q36263201-EE6B58C4-F99D-49B1-B5D1-A192BE895842 Q36352174-88D3BA76-FEBB-4515-8260-72A1ABD2BD38 Q36679906-6FA56BBA-65E2-4AAC-BAF2-B2087F1FC3FC Q37215856-D139F659-9BCE-48A7-B73A-4102F3DB052C Q37308443-F00D9368-4984-4DCD-9FD4-B5C01B829555 Q37464172-E4574BD5-4A4A-46D3-8911-98296272E96F Q37799838-9674E40E-BB2B-4337-915D-A0A518B9A453 Q37957126-256A497A-F54E-42DA-B549-8B3D73928281 Q38014896-15E6B6B1-E62E-4FB2-A767-1E5893BE94FB Q38100669-561C42A3-9AD8-47C2-A5F4-41395BA753FB Q38109630-A981132A-0CC2-4C6E-A4DC-7880FDC3B980 Q38237519-6E8814EF-FA22-4448-8D7C-1E7D011D8559 Q38362089-455B9FA2-4880-4225-9770-042C328B042A Q39747442-4DB87DA2-4EA3-420E-B934-9810D477EA86 Q42019923-A795E5DB-C99B-4A9C-B619-4FDAB74B02C7 Q42367948-4F22C5FD-E366-42D3-895A-B86FBA07BED3 Q46458603-96FAE529-160E-4063-9A29-C39820B5D574 Q50583728-403ED83D-654B-4EC2-B3DB-360DD9D34DF8 Q51760893-E9FC110B-4FF1-4645-B00E-BBFF30EB3CDB Q57492442-5520EB8B-2582-4C2D-9E65-08C7C03D4ABC Q58842294-CDCA840C-0599-454C-9502-47B31A5E8C22 Q59137566-592EBFB6-3EFC-435C-8A3E-EF024534D8D9

P2860

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.

http://www.wikidata.org/entity/Q45711274

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.

@en

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.

@nl

type

label

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.

@en

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.

@nl

prefLabel

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.

@en

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.

@nl

P1433

Q45711274-8824BEFF-FBBC-4ABC-AACC-5FD3566E1C72

P1476

Q45711274-7A3F3229-674F-4996-BA44-62C260D16788

P2093

Q45711274-51FBFC87-620D-4F3F-B672-78098B8B8829

Q45711274-562AEB9F-355A-4FC8-BC59-CD5E8972CDF9

Q45711274-6FE26D09-9857-4B97-BBDF-F7FBAC64DCE1

Q45711274-8D9A96A3-89B4-4A2D-8B96-64B51BB78B45

Q45711274-A3A4C9FA-EE30-4027-A285-1EC28086B0B1

Q45711274-E7908BA9-7717-4B61-BDD1-AA6F554EBA4F

P2860

Q45711274-0650C175-121E-444A-B35F-32B910B4BD62

Q45711274-1A0441BF-4361-4C79-B4AA-C9A4CC11E4C9

Q45711274-1A1FDCB2-88D2-4ABC-9AE5-BFA7AE2841A2

Q45711274-21684409-7C6D-4D7D-BC41-44E20EF2315F

Q45711274-34C8C67C-24DB-419A-A827-99CC1A50B44B

Q45711274-35BB9878-6DE1-42F6-AF73-39FDD22E7CAA

Q45711274-3ADE669E-CFE3-4944-93C2-8AE51FE11E4F

Q45711274-3BAA57F8-7415-47DD-ABCB-FCEB72501473

Q45711274-3D1F9310-FE53-465B-8D90-AB1BBA6C37A9

Q45711274-3FA63FCC-930E-4960-8BE1-124DF22D52E4

P304

Q45711274-9A9B41CC-4A68-4D90-9F7C-675A5C9454A7

P31

Q45711274-CF0751C8-398B-43B9-AFDB-4C04089E30DF

P356

Q45711274-4D623DA6-C72C-40B5-B50C-E4270A3165E8

P433

Q45711274-8AED7643-7D0A-4219-AE28-0E6383CEFE15

P478

Q45711274-BBF143E3-565A-4917-AAB8-915D006D3AB3

P50

Q45711274-138BEDDC-8192-4BF4-BE0A-4329E8CAA3FD

Q45711274-3C9AE08F-FE24-409B-B536-4A4263C62001

Q45711274-DE8A26B0-F3CE-45B7-A5A3-BAEB78CE5987

P577

Q45711274-3AE5C0EE-1AC8-4F96-99B3-7615570C48BA

P5875

Q45711274-C9219E2D-E3E1-46D5-9BA1-26E99951C0F6

P698

Q45711274-E67AC045-16F8-444C-A6CE-5131B93093CA

P921

Q45711274-83F94C5F-A5CF-43B4-9B93-C91A011E7201

P356

J.1365-2362.2002.00933.X

P1433

European Journal of Clinical Investigation

P1476

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients

@en

P2093

A Colloca

http://www.w3.org/2001/XMLSchema#string

A Finazzi-Agró

http://www.w3.org/2001/XMLSchema#string

F Moffa

http://www.w3.org/2001/XMLSchema#string

L Rossi

http://www.w3.org/2001/XMLSchema#string

M Cortesi

http://www.w3.org/2001/XMLSchema#string

P M Rossini

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Development and validation of a geriatric depression screening scale: a preliminary report

Redox metals and neurodegenerative disease.

Mounting evidence for the involvement of zinc and copper in Alzheimer's disease.

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

Iron accumulation in Alzheimer disease is a source of redox-generated free radicals.

The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery.

Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc.

P304

51-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2362.2002.00933.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Rosanna Squitti

Patrizio Pasqualetti

Emanuele Cassetta

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11509232

http://www.w3.org/2001/XMLSchema#string

P698

11851727

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease